Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Pfizer Inc. (NYSE: PFE ), the New York-headquartered Pharma giant whose share price—notwithstanding a rise to the dizzy heights of $60 per share during the pandemic, thanks to the success of its COVID vaccine Comir ...